Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Adefovir dipivoxil

Adefovir dipivoxil: 1 brand, 2 generics; first approved Sep 20, 2002; generic available.

Generic availableHas discontinued products
Generic status & protection

Generic available: 2 ANDA applications approved.

Brands (NDA)
1
Generics (ANDA)
2
Listed patents
0
Presentations
3

Brand (NDA) products

Originator applications
  • NDA 0214492002
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGTABLETORALDiscontinued

Generic (ANDA) products (2)

Abbreviated applications
  • ADEFOVIR DIPIVOXIL
    ANDA 2054592018
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGTABLETORALRxAB
  • ADEFOVIR DIPIVOXILRS
    ANDA 2020512013
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGTABLETORALRxAB

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Approval history

FDA approval span
First approval
24 yr 3 mo ago
Most recent approval
8 yr 3 mo ago

Approvals span 2002–2018 across 3 FDA applications.

Brand (NDA) 133%
Generic (ANDA) 267%

Adefovir dipivoxil: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.